Milestone Pharmaceuticals (MIST) Q4 2025 Earnings Beat: CARDAMYST Launch & EMA Update

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) Reports Earnings Beat Amid Launch Progress and Regulatory Timeline Adjustment

• MIST reported an EPS of -$0.16 for Q4 2025, beating the consensus estimate of -$0.18 (by $0.02). This was a positive surprise relative to expectations.
• Revenue was approximately $1.5 million, which beat the prior consensus estimate of around $1.20 million for that period. 
• The company announced a minor delay in the European approval timeline for etripamil (conditionally branded TACHYMIST™ in Europe): The European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) earlier, but a decision is now expected in the first half of 2027 (shifted from an initial Q1 2027 projection). This contributed to stock volatility post-earnings.
• Note: The U.S. FDA approved etripamil as CARDAMYST™ (nasal spray) in December 2025 for self-administered treatment of paroxysmal supraventricular tachycardia (PSVT) in adults. The launch is underway, with initial revenue recognized in Q4 2025.

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) is a biopharmaceutical company focused on innovative cardiovascular treatments. Its lead product, CARDAMYST™ (etripamil) nasal spray, is the first FDA-approved self-administered option for acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT), a condition causing sudden rapid heartbeats. The company is advancing commercialization in the U.S. while pursuing European approval.

On March 20, 2026, MIST reported Q4 2025 results for the period ending December 31, 2025. The EPS of -$0.16 beat estimates, reflecting controlled expenses and initial revenue from licensing/launch activities post-FDA approval. Revenue of around $1.5 million exceeded some lower consensus figures but fell well short of outlier higher estimates.

The European regulatory process for etripamil continues, with the EMA's MAA under review and a decision anticipated in the first half of 2027. This adjustment from earlier timelines has been noted as a factor in recent stock pressure, though U.S. launch momentum remains a key positive.

Financial metrics show ongoing lack of profitability typical for a clinical-stage-to-commercial-transition biotech: a negative P/E ratio (around -1.44 or similar based on trailing losses), and high price-to-sales ratios reflecting investor expectations for future growth from CARDAMYST.

Despite challenges, MIST maintains a strong liquidity position. The current ratio is reported around 8.0–8.2 in recent analyses, indicating solid short-term asset coverage of liabilities. Pro forma cash reserves support operations into 2027, providing runway for the U.S. CARDAMYST launch, further pipeline development (e.g., potential expansions to atrial fibrillation with rapid ventricular rate), and regulatory efforts.

Overall, while the quarter highlighted typical biotech hurdles (limited near-term revenue, regulatory timing adjustments), the earnings beat, initial sales traction, and robust cash position underscore resilience and potential upside from the recent FDA approval and commercial rollout. Investors should monitor launch progress and any further EMA updates for 2027.